None listed
Conditions
Brief summary
Asthma is an inflammatory disease of the airways that affects over 7% of the world’s population (Papi et al., 2018). Exercise-induced bronchoconstriction (EIB) is a type of asthma which is defined as a transient narrowing of the airways in response to exercise and affects 90% of asthma sufferers and up to 15% of non-asthmatic individuals (Bonini & Usmani, 2018). Asthma and EIB can be managed either by rapid bronchodilatation to relieve respiratory symptoms or long-term suppression of inflammation. However, frequent use of reliever medicines can lead to the user becoming tolerant to the treatment and long-term control medicines have several undesirable side effects. Dietary and supplement interventions have been reported to reduce the effects of asthma and EIB (Williams et al., 2016). These may represent a cost-saving, effective and safe method for reducing the incidence of asthmatic attacks. Anthocyanins are coloured pigments that are responsible for the colours red, purple and blue in fruits and vegetables. Current animal studies have found that after consumption of anthocyanins, inflammation was reduced, and lung function was improved (Park et al., 2007). Whether anthocyanins could improve respiratory symptoms and lung function in otherwise healthy humans with EIB is unknown. This will be the first study to determine the role anthocyanins have on lung function and inflammation in individuals with EIB.
Interventions
The intervention will be six capsules of CurraNZ New Zealand blackcurrant extract capsules (manufactured in Surrey, United Kingdom), the equivalent to 105 mg anthocyanins per capsule. The dosage will equal 630 mg anthocyanin daily for the 28 days of intervention. Safety profiles conducted o/s have shown no adverse effects and a toxicity LD50 = 2,000 mg/kg. Previous studies have not reported adverse effects from this product. Packaging will be divided into individual mylar bags for each day. At t
The intervention will be six capsules of CurraNZ New Zealand blackcurrant extract capsules (manufactured in Surrey, United Kingdom), the equivalent to 105 mg anthocyanins per capsule. The dosage will equal 630 mg anthocyanin daily for the 28 days of intervention. Safety profiles conducted o/s have shown no adverse effects and a toxicity LD50 = 2,000 mg/kg. Previous studies have not reported adverse effects from this product. Packaging will be divided into individual mylar bags for each day. At the end of the intervention, the return of the empty bags will be used to monitor adherence. The 14-day washout period has been calculated via the recommendation of 10x the elimination half-life. The half-life for anthocyanin ranges between 12 and 51 hours The 14-day washout period has been calculated via the recommendation of 10x the elimination half-life. The half-life for anthocyanin ranges between 12 and 51 hours.
Sponsors
Lauren Brook
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject)
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
Inclusion criteria: • Aged between 18 and 40 years of age. • BMI (kg/m2) 18-35 • Exercise-induced bronchoconstriction (EIB) – Physician-diagnosed EIB, Fall >10% forced expiratory volume in 1 second (FEV1) following eucapnic voluntary hyperpnoea (EVH). • Medications -Asthma medications • Chronic diseases - Healthy individuals except diagnosis of EIB • Smoking - Non-smoker
Exclusion criteria
None.
Outcome results
None listed